PSTM Abstract Supplement study demonstrated the safety and effectiveness of this product in correcting atrophic acne scars. Results of the 6-month endpoint was previously described in Karnik et al. 2 To determine the continued benefit of PMMA-collagen for atrophic acne scars, and confirm the original findings over a longer time period, the study was continued through 12 months follow up.
Subjects were randomized in a 2:1 ratio to PMMA-collagen or saline (control). Subjects received up to 2 injections per scar and followed for 12 months. Evaluations were performed by treating and blinded investigators and subject self-assessments. Success was determined by an improvement of 2 points on the ASRS by at least 50% of treated scars. At month 6, the blind was removed and control subjects were given the option to receive treatment with PMMA-collagen. All subjects were followed for 12 months following last PMMA-collagen injection.
results: 147 subjects enrolled and underwent treatment. At 6 months 64.4% of PMMA-treated subjects were graded as responders compared to 32.6% of the control subjects (p = 0.0005). Improvement with PMMA-collagen was durable over time as noted by the ASRS response rates of 61.5% and 70.7% at Month 9 and 12 respectively. High scores were observed for subjective endpoints on GAIS with 97.6% and 83.1% of physicians and subjects respectively noting improvement. Subjects expressed a high degree of satisfaction (90.4%) with the amount of scar correction. PMMA-collagen showed excellent safety with generally mild, reversible adverse events. No significant differences in efficacy or safety were noted between genders, for darker skin types, or in older age groups. PMMA-treated subjects followed for 12 months continued to show an excellent safety profile. discussion: PMMA-collagen demonstrates substantial effectiveness in the treatment of atrophic acne scars while maintaining an excellent safety profile. introduction: Facial erythema and hyperpigmentation are common cosmetic concerns that are caused by a variety of factors, although increased production of reactive oxygen species (ROS) has been identified as a key contributor for both conditions. 1,2 We hypothesized that oral antioxidant supplementation could minimize skin ROS production and reduce the severity of both erythema and hyperpigmentation. We evaluated the clinical efficacy of two dietary supplements containing a gliadin-bound, melon-derived superoxide dismutase (SOD) antioxidant extract that were developed to address skin pigmentation and inflammation.
references
Method: A 90-day multicenter randomized, placebo-controlled, single-blinded clinical trial of 36 participants with a history of either facial photodamage or an inflammatory skin condition. Participants with photodamage were randomized to the brightening formula (BF) treatment group or BF placebo group. Participants with facial inflammation were randomized to the anti-inflammatory formula (AIF) treatment group or AIF placebo group. Red and brown pigmentation were assessed using VECTRA XT 3D images taken at days 0, 30 and 90 of treatment. Participants evaluated their subjective skin satisfaction before and after 90 days of treatment using a set of seven 100-mm visual analog scale (VAS) questions that assed skin radiance/glow, redness, irritation, pigment/brown spots, softness/feel, dryness, and overall quality. results: No significant changes in total pigmentation occurred at 30 days in any of the treatment groups. After 90 days of treatment, total redness in the AIF group was reduced from 52.20 ± 12.57% to 44.96 ± 9.24% (p = 0.008). Total brown pigmentation was reduced from 73.77 ± 12.69% to 69.15 ± 13.56% (p = 0.042) in the BF group, with a decrease in total dark spots from 20.47 ± 16.57 to 13.76 ± 12.04 (p = 0.010). No significant changes in total redness or brown pigmentation occurred in either of the control groups (p = 0.75 and 0.89). At 90 days, VAS scores were significantly improved for radiance, brown spots and dryness in the AIF group (p < 0.05), with no significant changes in the placebo group. Radiance, softness and overall quality scores were significantly improved in the BF group. The BF placebo group reported significant improvements in brown spot and dryness scores.
conclusion: This study suggests that the AIF and BF supplements provide significant clinical benefits in the reduction of facial erythema and hyperpigmentation. introduction: Facial burns often get an inextricable situation in terms of healing and long-term morbidity. Many different procedures were used to overcome these challenging topics. Although results were more promising in terms of surgeons, is inadequate for patients. We present the efficiency of fractional CO2 laser(FL), Adipose-Derived stem cells(ADSC), Regenerative Epithelial Suspension(Recell®) and lipoinjection combination treatment on facial hypertrophic scars due to burns(FS). 
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